Letter to the editor reply

Dear Sirs,

We would like to thank the authors for their remarks on our paper “Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women” in which the association between MDM2 SNP309 polymorphism and endometrial cancer (EC) risk in the Polish population was investigated. In this paper we reported a significant positive association between the MDM2 SNP309GG genotype and endometrial carcinoma. This is the first study linking single nucleotide polymorphisms of the MDM2 gene with EC incidence in the population of Polish women.

Our study contained a limited number of individuals. In the paper we suggested that further studies conducted on a larger group are needed to clarify that MDM2 SNP309 polymorphism may be a predictive factor for endometrial cancer in Poland. The observed differences in statistical results may be associated with the use of various statistical methods.

We agree that a second MDM2 promoter SNP285 polymorphism is very important. Its location in the promoter region indicated its possible role in the regulation of transcription of the MDM2 gene. We investigated MDM2 SNP309 polymorphism because literature data suggested that this polymorphism may be very significant in EC development. Moreover, among the variants of the MDM2 gene SNP309 was most frequently studied and its role is still unknown. The literature data are inconsistent. In conclusion, further research, conducted on a larger population, is needed to clarify the significance of MDM2 polymorphisms not only in EC but also in other cancers.